Immuneering Shares Surge on Trial Data

Immuneering Corp shares jumped 12.5% in after‑hours trading after releasing Phase 2a pancreatic cancer data.
Median overall survival reached 17.3 months for 55 first‑line metastatic patients treated with atebimetinib plus modified gemcitabine/nab‑paclitaxel.
Grade 3+ adverse events occurred in ≥10% of patients, with anemia at 16% and neutropenia at 18%, deemed tolerable.
Phase 3 MAPKeeper 301 trial is recruiting, aiming to dose first patient mid‑2026; full data to be presented at ASCO on June 1, 2026.